February 12, 2018 / 10:08 AM / a year ago

Norway to buy Biogen's Spinraza medicine - broadcaster NRK

A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder

OSLO (Reuters) - Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc(BIIB.O) at a cost of 7 million Norwegian crowns (635,883.95 pounds) per year per patient, public broadcaster NRK reported on Monday.

Spinraza treats the rare, often fatal disease spinal muscular atrophy (SMA). Norwegian authorities will cover the costs for minors only.

Reporting by Gwladys Fouche, editing by Terje Solsvik

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below